Drug Development in Dementia


From bench to bedside, drug development is the process of bringing a novel drug to market. As a progressive and irreversible decline in cognition, dementia affects a patient's pre-existing level of functioning, according to its definition. Alzheimer's disease (AD) is the most common cause of the clinical syndrome of dementia. In Alzheimer's disease, drug development is based on pathophysiological theory that is constantly evolving.


  • Discovery & Development
  • Preclinical Research
  • Clinical Development
  • Post-market Monitoring

Related Conference of Drug Development in Dementia

April 23-24, 2026

8th World Depression Congress

Paris, France
May 14-15, 2026

9th World Conference on Neuroscience

Rome, Italy
June 22-23, 2026

7th World Congress on Sleep Disorders and Therapeutics

Amsterdam, Netherlands
June 22-23, 2026

38th World Conference on Neurology

Barcelona, Spain
June 22-23, 2026

18th Global Neurologists Meeting on Neurology and Neurosurgery

Amsterdam, Netherlands
June 29-30, 2026

39th European Neurology Congress

London, UK
June 29-30, 2026

37th Conference on Clinical Neuroscience and Neurogenetics

Aix-en-Provence, France
July 20-21, 2026

37th World Congress on Neurology and Neuroscience

Amsterdam, Netherlands
July 23-24, 2026

16th Global Alzheimers Summit

Paris, France
July 23-24, 2026

14th International Conference on Cannabis & Medicinal Research

Amsterdam, Netherlands
September 18-19, 2026

21st Annual Congress on Neuroscience

Dubai, UAE
November 16-17, 2026

8th World Brain Congress

Tokyo, Japan

Drug Development in Dementia Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in